Erasca Secures $64 Million Series A Funding to Advance Next-Generation Oncology Therapies and AI Drug Discovery Platform

VCBeat (WeChat Official Account: vcbeat) has learned that U.S. biotechnology company Erasca recently announced the completion of a $64 million Series A financing round. The proceeds from this round will be used to develop novel drugs, accelerate the construction of Erasca’s artificial intelligence platform, and advance the development of next-generation oncology therapeutics. Investors include ARCH Venture Partners, Andreessen Horowitz, Reneo Capital, as well as other private and strategic investors.

Jonathan E. Lim, M.D., Co-founder and Executive Chairman of Erasca, stated, “Cancer is an adversary of humanity. Whether through external innovation or internal development of artificial intelligence, we must commit to leveraging all available tools to defeat it. The support from world-class life sciences investors, combined with the AI expertise of Silicon Valley investors, will help accelerate and enhance the quality of our product R&D and AI platform development, ultimately benefiting all of mankind.”

Influenced by the latest scientific discoveries and encouraged by the effective development of various biologics for cancer, Erasca is conducting research on multiple cancer therapy projects. To address the most challenging problems in oncology, Erasca is seeking out the biological drivers of cancer—undisclosed targets. By maintaining an open mind toward possibilities, Erasca’s research team will reposition potential new mechanisms in precision oncology. Their research aims not merely to treat cancer, but to fundamentally cure it.

Kristina Burow, General Partner at ARCH Venture Partners, stated, “With Erasca’s enterprise-building capabilities, cutting-edge drug discovery platform, and the high-caliber team assembled by Jonathan, I believe it will have a significant impact on treatment outcomes for cancer patients.”

Jorge Conde, General Partner at Andreessen Horowitz, added, “While technology has transformed every aspect of our lives, drug development remains challenging. It is costly and prone to errors.” Erasca’s experienced team integrates artificial intelligence with drug discovery to fundamentally develop strategies for combating cancer, demonstrating their commitment to curing the disease.

OPRA, short for Oncology Pattern Recognition Algorithm, is Erasca’s proprietary artificial intelligence drug discovery platform. Leveraging advanced computational tools such as machine learning, the platform develops innovative oncology therapeutic strategies without relying on any specific drug or a single approach to cancer treatment. It accelerates drug discovery by shutting down cancer pathways through a single-agent combination approach. By analyzing large-scale datasets from both China and abroad, OPRA enables Erasca’s scientists to interrogate key oncogenic drivers within vast amounts of cancer biology data.

OPRA’s data-driven medical approach is highly flexible, supporting the parallel deployment of multiple programs. OPRA also leverages Erasca’s drug discovery process to enable scientists and artificial intelligence to accelerate the development of therapies with maximal potency during R&D, thereby advancing its ultimate goal of curing cancer.

Erasca, founded in 2018 and headquartered in San Diego, is a company dedicated to developing therapies to eliminate cancer. Erasca has assembled an experienced research team that is advancing multiple programs targeting the biological drivers of cancer, while seeking additional research and collaboration opportunities through academic and biopharmaceutical partnerships.

In October 2018, Erasca completed a $42 million Series A financing round, led by City Hill Ventures and Cormorant Asset Management. In March 2019, Erasca secured an additional $22 million in follow-on funding, bringing the total Series A financing to $64 million, with new investors ARCH Venture Partners and Andreessen Horowitz participating.

(Compiled by Wang Shuijing)